This study consists of a 5-week screening period, a double-blind treatment period divided into phase A and phase B. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either Telitacicept 240mg or placebo. Subjects will be given SC Telitacicept or placebo once a week for a total of 39 doses in phase A and once every 2 weeks for a total of 32 doses in phase B.~Primary endpoint of phase A will be measured at week 39. Primary endpoint of phase B will be measured at week 104.
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy.